A Roche Holding AG study of its experimental breast-cancer drug in combination with another treatment failed to meet the ...
A one‑year course of T‑DM1 offers excellent cancer‑free survival for early HER2‑positive breast cancer, with far less nerve ...
It may be best not to go off-script when it comes to breast cancer. Roughly 1 in 8 US women are expected to be diagnosed with invasive breast cancer at some point. It’s the most common cancer in women ...
The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT ...
Roche's shares dropped more than 5% on Monday as the Swiss drugmaker failed to show that its promising breast cancer drug ...
In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...
Roche Holdings AG on Monday shared results from the phase 3 persevERA Breast Cancer study of giredestrant combined with palbociclib in advanced cancer patients. Trial Misses Primary Goal The trial ...
Exhaustion creeps in. Appetite vanishes. Hair thins. The person in the mirror looks gaunt. It's the paradox of cancer treatment: The same drugs meant to save a life can also wear the body down. Nick ...
MedPage Today on MSN
GLP-1 drugs may benefit cancer patients with brain lesions
Retrospective study finds link between blockbuster drugs and longer survival ...
During the Miami Breast Cancer Conference, CURE discussed ADCs with Dr. Kevin Kalinsky.
Cancer drug pulled market as Ipsen removes Tazverik from the U.S. due to secondary blood cancer risks reported in clinical trials.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results